5 unknown, 3 completed, 3 terminated, 2 active not recruiting. 7 Phase 2, 4 Phase 3, 3 Phase 1, 1 Not applicable.
Follow Deafness, Autosomal Recessive 39: new trials by email Literature Review of Deafness, Autosomal Recessive 39 trials Research Report on Deafness, Autosomal Recessive 39
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Additional Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury KP-100IT - Acute Spinal Cord Injury (SCI) | Phase 3 | Not yet recruiting | Kringle Pharma, Inc. | 10 | 2026-07-31 | 2026-07-23 |
| Phase 3 Study of KP-100LI in Subjects With Vocal Fold Scar KP-100LI, Placebo - Vocal Fold Scar | Phase 3 | Active not recruiting | Kringle Pharma, Inc. | 62 | 2022-12-01 | 2026-07-06 |
| Angiogenesis and Blood Perfusion Effect of HGF Gene Therapy in PAD Patients NL003, Placebo - Peripheral Artery Disease | Phase 3 | Unknown | Beijing Northland Biotech. Co., Ltd. | 36 | 2022-07-29 | 2023-08-01 |
| ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies (SHAPE Trial) ATH-1017, Placebo - Parkinson Disease Dementia, Dementia With Lewy Bodies | Phase 2 | Terminated | LeonaBio | 28 | 2022-01-20 | 2025-03-04 |
| Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE) Tepotinib, Cetuximab - Colorectal Neoplasms | Phase 2 | Terminated | EMD Serono Research & Development Institute, Inc. | 3 | 2021-01-28 | 2022-12-22 |
| Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury KP-100IT - Acute Spinal Cord Injury | Phase 3 | Unknown | Kringle Pharma, Inc. | 25 | 2020-07-13 | 2022-08-26 |
| A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer REGN5093 - NSCLC | Phase 1 / Phase 2 | Active not recruiting | Regeneron Pharmaceuticals | 95 | 2020-01-07 | 2026-09-16 |
| Rapid Test for Detection of the Focus of Infection in Post Neurosurgical Patients. Infection, Bacterial, Antibiotic Resistant Infection | Unknown | Fariba Nayeri | 150 | 2015-12-02 | 2017-08-21 | |
| Phase I/II Study of KP-100IT in Acute Spinal Cord Injury KP-100IT, Placebo - Spinal Cord Injuries | Phase 1 / Phase 2 | Completed | Kringle Pharma, Inc. | 45 | 2014-06-30 | 2019-06-05 |
| Safety Study of Adenovirus Hepatocyte Growth Factor to Treat Ischemic Heart Disease Ad-HGF - Ischemic Heart Disease | Phase 1 / Phase 2 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 40 | 2012-11-01 | 2013-08-20 |
| Study to Evaluate the Safety and Activity of BB3 to Treat Heart Attack BB3, Normal saline - Myocardial Infarction | Phase 2 | Terminated | Angion Biomedica Corp | 5 | 2012-07-01 | 2014-11-21 |
| Study on Delayed Graft Function Using Paired Kidneys BB3, Normal Saline - Delayed Graft Function | Phase 2 | Unknown | Angion Biomedica Corp | 12 | 2011-08-01 | 2016-02-22 |
| Vascular Endothelial Growth Factor (VEGF), Platelet Derived Growth Factor (PDGF), Hepatocyte Growth Factor (HGF) in Patients With Acute Coronary Syndrome (ACS) Acute Coronary Syndrome | Completed | National Institute of Cardiology, Warsaw, Poland | 120 | 2007-01-01 | 2010-05-27 | |
| The Role of Atorvastatin on Monocyte Function in Patients With Coronary Artery Disease and Hypercholesterolemia atorvastatin (drug) - Coronary Artery Disease, Hypercholesterolemia | Not applicable | Completed | University of Ulm | 50 | 2002-05-01 | 2006-05-24 |
Acute Coronary Syndrome (1) · Adenoviridae Infections (1) · Bacterial Infections (1) · Carcinoma, Non-Small-Cell Lung (1) · Chemotaxis (1) · Colorectal Neoplasms (1) · Coronary Artery Disease (1) · Cross Infection (1) · Delayed Graft Function (1) · Dementia (1) · Hypercholesterolemia (1) · Lewy Body Disease (1) · Meningitis (1) · Meningitis, Bacterial (1)
Cardiovascular Diseases (5) · Vascular Diseases (5) · Heart Diseases (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Central Nervous System Diseases (3) · Myocardial Ischemia (3) · Nervous System Diseases (3) · Arterial Occlusive Diseases (2) · Arteriosclerosis (2) · Infections (2) · Neoplasms (2) · Neoplasms by Site (2) · Atherosclerosis (1) · Bacterial Infections and Mycoses (1)
Hepatocyte Growth Factor (3) · Saline Solution (3) · Atorvastatin (1) · Cetuximab (1) · Pharmaceutical Preparations (1) · tepotinib (1)
Kringle Pharma, Inc. (4) · Angion Biomedica Corp (2) · Beijing Northland Biotech. Co., Ltd. (1) · EMD Serono Research & Development Institute, Inc. (1) · Fariba Nayeri (1) · LeonaBio (1) · National Institute of Cardiology, Warsaw, Poland (1) · Regeneron Pharmaceuticals (1) · The First Affiliated Hospital with Nanjing Medical University (1) · University of Ulm (1)
Japan (4) · United States (4) · China (2) · France (2) · Spain (2) · United Kingdom (2) · Belgium (1) · Czechia (1) · Germany (1) · Italy (1) · Netherlands (1) · Poland (1) · Russia (1) · South Korea (1) · Sweden (1)
Anna Konopka, PhD (1) · Daichika Hayata (1) · Etsuro Hashimura (1) · Johannes Waltenberger, MD PhD (1) · Weizhong Cai (1) · Zhijian Yang, PhD. (1)
PMID 19939200, PMID 23313225, PMID 24049022
2019 (1), 2023 (1), R44DK078455 (1), R44HL091699 (1)